Ifosfamide
Active ingredient: Ifosfamide
In short: Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.
What is Ifosfamide used for?
Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.
âš Boxed warning (FDA's strongest warning)
•Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle .
•Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy .
•Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna .
Ifosfamide dosage
Administer Ifosfamide for Injection with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day to reduce the incidence or severity of bladder toxicity.
Administer Ifosfamide for Injection with mesna to reduce the incidence or severity of hemorrhagic cystitis .
The recommended dosage of Ifosfamide for Injection is 1.2 grams per m2 per day administered as a slow intravenous infusion (lasting at least 30 minutes) for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from hematologic toxicity.
Individualize the dose and dosing schedule of Ifosfamide for Injection based on patient risk factors and adverse reactions.
Ifosfamide for Injection is a hazardous drug. Follow applicable special handling and disposal procedures.1
Skin reactions associated with accidental exposure to Ifosfamide for Injection may occur. To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and solutions containing Ifosfamide for Injection. If Ifosfamide for Injection solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water.
Prepare Ifosfamide for Injection for intravenous use by adding Sterile Water for Injection, USP or Bacteriostatic Water for Injection, USP (benzyl alcohol or parabens preserved) to the vial and shaking to dissolve. Before administration, the substance must be completely dissolved. Use the quantity of diluents shown in Table 1
below to reconstitute the product:
Dosage Strength | Quantity of Diluent | Final Concentration
1 gram | 20 mL | 50 mg per mL
3 grams | 60 mL | 50 mg per mL
Solutions of ifosfamide may be diluted further to achieve concentrations of 0.6 to 20 mg/mL in the following fluids:
•5% Dextrose Injection, USP
•0.9% Sodium Chloride Injection, USP
•Lactated Ringer’s Injections, USP
•Sterile Water for Injection, USP
Because essentially identical stability results were obtained for Sterile Water admixtures as for the other admixtures (5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer’s Injection), the use of large volume parenteral glass bottles, VIAFLEX bags or PAB bags that contain intermediate concentrations or mixtures of excipients (e.g., 2.5% Dextrose Injection, 0.45% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection) is also acceptable.
Refrigerate constituted or constituted and further diluted solutions of Ifosfamide for Injection and use within 24 hours. Benzyl-alcohol-containing solutions can reduce the stability of ifosfamide.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
How to take Ifosfamide — instructions & advice from the label
Myelosuppression
•Advise patients that treatment with Ifosfamide for Injection may cause myelosuppression which can be severe and lead to infections and fatal outcomes.
•Inform patients of the risks associated with the use of Ifosfamide for Injection and plan for regular blood monitoring during therapy .
•Inform patients to report fever or other symptoms of an infection .
•Advise patients on the risks of bleeding and anemia , Use in Specific Populations (8.1)].
Encephalopathy
•Advise patients on the risk of encephalopathy and other neurotoxic effects with fatal outcome .
•Inform patients that Ifosfamide for Injection may impair the ability to operate an automobile or other heavy machinery .
Nephrotoxicity and Urotoxicity
•Advise patients on the risk of bladder and kidney toxicity.
•Advise patients of the need to increase fluid intake and frequent voiding to prevent accumulation in the bladder .
Cardiotoxicity
•Advise patients on the risk of cardiotoxicity and fatal outcome.
•Advise patients to report preexisting cardiac disease and manifestations of cardiotoxicity . …
Warnings & precautions
Do not take this medicine if: Ifosfamide for Injection is contraindicated in patients with:
•Known hypersensitivity to administration of ifosfamide.
•Urinary outflow obstruction.
Ifosfamide for Injection can cause myelosuppression that results in severe or fatal infections including sepsis or septic shock. Ifosfamide‑induced myelosuppression includes leukopenia, neutropenia, thrombocytopenia (with bleeding events), and anemia. The nadir of the leukocyte count usually occurs during the second week after administration of Ifosfamide for Injection. The risk of myelosuppression is dose‑dependent and increased in patients with reduced renal function, bone marrow metastases, prior radiation, and concomitant or prior therapy with other cytotoxic agents.
Monitor complete blood counts, including leukocytes, neutrophils, platelets, and hemoglobin prior to each administration of Ifosfamide for Injection, at appropriate intervals during treatment, and as clinically indicated.
Myelosuppression may require dosage delays. Avoid administration of Ifosfamide for Injection to patients with a WBC count below 2000/µL, a platelet count below 50,000/µL, or when signs or symptoms of active infection or severe immunosuppression are present.
Ifosfamide for Injection can cause encephalopathy which may be fatal. Signs and symptoms may include confusion, somnolence, coma, hallucination, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, and seizures.
Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use.
Signs and symptoms may occur or recur within hours to days after administration of Ifosfamide for Injection. Continue supportive care until complete resolution of CNS signs and symptoms. …
Ifosfamide side effects
Because clinical trials are conducted from widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The adverse reactions in Table 2 below are based on 30 publications describing clinical experience with fractionated administration of ifosfamide as a single agent with a total dose of 4 to 12 g/m2 per course.
Adverse Reaction | Single Agent Ifosfamide for Injection%(number of patients)
Skin and Subcutaneous Tissue Disorders
Alopecia | 90%
(540/603)
Dermatitis | 0.08%
(1/1317)
Papular rash | 0.08%
(1/1317)
Gastrointestinal Disorders
Nausea/Vomiting | 47%
(443/964)
Diarrhea | 0.7%
(9/1317)
Stomatitis | 0.3%
(4/1317)
Renal and Urinary Disorders
Hemorrhagic cystitisIncludes dysuria and pollakiuria
Hematuria
- without mesna | 44%
(282/640)
- with mesna | 21%
(33/155)
Macrohematuria
- without mesna | 11%
(66/594)
- with mesna | 5%
(5/97)
Renal dysfunctionIncludes acute renal failure, irreversible renal failure (fatal outcomes) serum creatinine increased, BUN increased, creatinine clearance decreased, metabolic acidosis, anuria, oliguria, glycosuria, hyponatremia, uremia, creatinine clearance increased | --
Renal structural damageIncludes acute tubular necrosis, renal parenchymal damage, enzymuria, cylindruria, proteinuria | --
Blood and Lymphatic System Disorders
LeukopeniaIncludes neutropenia, granulocytopenia, …
Drug interactions
CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites. CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.
CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment.
About this medicine
Ifosfamide for Injection (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide.
Ifosfamide is a alkylating drug chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. Ifosfamide is 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide. The molecular formula is C7H15Cl2N2O2P and its molecular weight is 261.1. Ifosfamide is a white crystalline powder soluble in water. There are no excipients in the formulation. Each vial contains 1 gram or 3 grams of sterile ifosfamide alone.
Its structural formula is:
How it works: Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 91e433a9-6800-43a6-ac13-a49a04a5aecd. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate